Advertisement

AZN

AstraZeneca PLC

Healthcare · USD

Set alert

Price alert · AZN

All alert types
186.65 USD +12.25 +7.02%
As of Oct 30, 2026 Extended hours 186.35 -0.16%
Bid
186.63 × 100
Ask
186.75 × 300
183.10 Day range 188.39
155.62 52-week range 209.48
YTD
+1.52%
1 year
+13.34%
Open
183.59
Prev close
174.40
Mkt cap
289.48B
Vol
5.47M
Avg vol
3.41M
EPS
6.69
P/E
27.90
Div yield
1.84%
More statistics
Low
183.10
High
188.39
Forward P/E
16.41
Beta
0.21
Short ratio
1.14
Inst. own
76.35%
Dividend
3.20
Ex-div date
Aug 6, 2026
Earnings
Feb 9, 2027
50-d avg
164.04
200-d avg
180.19
1y target
206.66

5D chart

Chart tools
Interval
AZN five-day price chart168.0173.1178.2183.3188.4Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
288.78B
Enterprise value
297.95B
Trailing P/E
27.83
Forward P/E
16.41
PEG ratio
1.23
Price / sales
4.71
Price / book
5.74
EPS (TTM)
6.69
Beta
0.21
Dividend yield
1.84%
Payout ratio
46.95%
Profit margin
17.02%
Revenue (TTM)
61.37B
Revenue growth
6.40%
Free cash flow
5.12B
Total cash
4.97B
Total debt
32.35B
Return on equity
21.96%
Shares outstanding
1.55B
Short % of float
0.21%
50-day average
164.04
200-day average
180.19

Analyst view

Consensus: buy

Buy
Price target (mean) 206.66 +10.7% upside
Target (low)
158.00
Target (mean)
206.66
Target (high)
240.00
Ratings (0m) 12 9 buy · 2 hold · 1 sell
  • Strong buy2
  • Buy7
  • Hold2
  • Sell1
  • Strong sell0

Next earnings

Feb 9, 2027

Expected Feb 9, 2027. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
AZN Revenue — quarterly 15.38B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
AZN Net income — quarterly 2.51B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
AZN EPS — quarterly 1.61
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

AZN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 9, 2027Dec 30, 20262.41———
Oct 30, 2026Sep 30, 20262.602.79+0.19+7.31%
Jul 27, 2026Jun 30, 20262.502.63+0.13+5.20%
Apr 29, 2026Mar 31, 20262.572.58+0.01+0.39%
Feb 10, 2026Dec 31, 20252.092.12+0.03+1.44%
Nov 6, 2025Sep 30, 20252.282.38+0.10+4.39%

Upgrades / downgrades

AZN analyst upgrades and downgrades
DateFirmActionFromTo
Aug 24, 2026CICCinit—Outperform
Feb 13, 2025UBSupNeutralBuy
Nov 20, 2024UBSupSellNeutral
Sep 11, 2024Erste GroupupHoldBuy
Aug 12, 2024TD CowenmainBuyBuy
May 30, 2024Argus ResearchmainBuyBuy

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United Kingdom

News

Your note

Sign in to keep a note on AZN — it syncs with the Stock Master app.

Insider holders

AZN insider holders
InsiderRelationLatest transactionDateShares held
BlackRock Financial Management, Inc.—Annual ReturnJan 30, 2026100,885,181
Broadley (Philip)—Annual ReturnDec 30, 20258,025
Demare (Michel)—BoughtSep 13, 202612,500
Investor AB—Annual ReturnJan 30, 202651,587,810
McCoy (Sherilyn S)—Annual ReturnDec 30, 20251,736
Mok (Tony Shu Kam)—Annual ReturnDec 30, 20253,500

Institution ownership

AZN institution ownership
Holder% heldSharesValueReported
Investor AB3.33%51,587,8109.61BJun 29, 2026
Vanguard Capital Management LLC2.93%45,386,1908.45BJun 29, 2026
Capital International Investors2.23%34,576,0706.44BJun 29, 2026
NORGES BANK2.18%33,864,1726.31BJun 29, 2026
Capital World Investors1.94%30,075,1345.60BJun 29, 2026
FMR, LLC1.86%28,895,2645.38BJun 29, 2026

Fund ownership

AZN fund ownership
Holder% heldSharesValueReported
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund1.42%22,045,6584.10BJul 30, 2026
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund0.95%14,666,2272.73BJun 29, 2026
VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund0.77%11,923,0742.22BJun 29, 2026
iShares Trust-iShares Core MSCI EAFE ETF0.74%11,467,6452.14BSep 29, 2026
NEW PERSPECTIVE FUND0.73%11,260,4042.10BSep 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund0.66%10,300,5051.92BJul 30, 2026
Advertisement